Founded in 2018, Celadon Pharmaceuticals is a UK based pharmaceutical company with a primary focus on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. Celadon also aims to conduct research into cannabinoids for use in chronic pain and other conditions such as autism and multiple sclerosis, within the highly regulated UK market.
Celadon has received the relevant licencing from the UK governance and approval of EU-GMP certification from the MHRA and will continue to work closely with the relevant UK regulators to be able to grow and supply medicinal cannabis with high tetrahydrocannabinol (THC) content in the UK, allowing us an opportunity to become the dominant player in what is expected to be a large and fast-growing UK market.
Founded in 2018, Celadon Pharmaceuticals is a UK based pharmaceutical company with a primary focus on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. Celadon also aims to conduct research into cannabinoids for use in chronic pain and other conditions such as autism and multiple sclerosis, within the highly regulated UK market.
Celadon has received the relevant licencing from the UK governance and approval of EU-GMP certification from the MHRA and will continue to work closely with the relevant UK regulators to be able to grow and supply medicinal cannabis with high tetrahydrocannabinol (THC) content in the UK, allowing us an opportunity to become the dominant player in what is expected to be a large and fast-growing UK market.
Input your search keywords and press Enter.